Deciphera Pharmaceuticals Management
Management criteria checks 3/4
Deciphera Pharmaceuticals' CEO is Steve Hoerter, appointed in Mar 2019, has a tenure of 5.25 years. total yearly compensation is $6.01M, comprised of 12.3% salary and 87.7% bonuses, including company stock and options. directly owns 0.084% of the company’s shares, worth $1.86M. The average tenure of the management team and the board of directors is 4.3 years and 9 years respectively.
Key information
Steve Hoerter
Chief executive officer
US$6.0m
Total compensation
| CEO salary percentage | 12.3% |
| CEO tenure | 5.3yrs |
| CEO ownership | 0.08% |
| Management average tenure | 4.3yrs |
| Board average tenure | 9yrs |
Recent management updates
Recent updates
Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up
Apr 30
Diving Into Deciphera Pharmaceuticals
Apr 26We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Mar 13We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 02Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?
Sep 25Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Jul 26Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)
Jun 22Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S
May 08We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Apr 10We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 29Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside
Aug 29Deciphera Pharmaceuticals Q2 2022 Earnings Preview
Aug 03We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully
Jul 29Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now
Feb 11Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified
Nov 22Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Aug 26Deciphera Pharmaceuticals posts data from cancer studies at ASCO21
Jun 04Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth
May 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$190m |
| Dec 31 2023 | US$6m | US$738k | -US$195m |
| Sep 30 2023 | n/a | n/a | -US$194m |
| Jun 30 2023 | n/a | n/a | -US$187m |
| Mar 31 2023 | n/a | n/a | -US$182m |
| Dec 31 2022 | US$4m | US$703k | -US$179m |
| Sep 30 2022 | n/a | n/a | -US$221m |
| Jun 30 2022 | n/a | n/a | -US$258m |
| Mar 31 2022 | n/a | n/a | -US$286m |
| Dec 31 2021 | US$9m | US$676k | -US$300m |
| Sep 30 2021 | n/a | n/a | -US$274m |
| Jun 30 2021 | n/a | n/a | -US$258m |
| Mar 31 2021 | n/a | n/a | -US$255m |
| Dec 31 2020 | US$8m | US$650k | -US$266m |
| Sep 30 2020 | n/a | n/a | -US$271m |
| Jun 30 2020 | n/a | n/a | -US$263m |
| Mar 31 2020 | n/a | n/a | -US$218m |
| Dec 31 2019 | US$9m | US$435k | -US$192m |
| Sep 30 2019 | n/a | n/a | -US$157m |
| Jun 30 2019 | n/a | n/a | -US$126m |
| Mar 31 2019 | n/a | n/a | -US$126m |
| Dec 31 2018 | US$447k | n/a | -US$100m |
Compensation vs Market: Steve's total compensation ($USD6.01M) is about average for companies of similar size in the US market ($USD5.66M).
Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.
CEO
Steve Hoerter (53 yo)
5.3yrs
Tenure
US$6,010,712
Compensation
Mr. Steven L. Hoerter, also known as Steve, serves as Director at ORIC Pharmaceuticals, Inc. since August 2021. He has been President and Chief Executive Officer of Deciphera Pharmaceuticals, Inc. since Ma...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.3yrs | US$6.01m | 0.084% $ 1.9m | |
| Executive VP | 9.3yrs | US$2.03m | 0.049% $ 1.1m | |
| Executive VP & Chief Scientific Officer | less than a year | US$3.06m | 0% $ 0 | |
| Senior VP & Chief Commercial Officer | 5.8yrs | US$1.58m | 0.036% $ 801.7k | |
| Executive VP & Chief Medical Officer | 4.7yrs | US$2.13m | 0.084% $ 1.8m | |
| Senior VP & Chief Technical Officer | less than a year | no data | no data | |
| Senior Vice President of Finance & Investor Relations | no data | no data | no data | |
| Senior VP & General Counsel | 5.3yrs | no data | no data | |
| Senior VP & Chief Human Resources Officer | 2.4yrs | no data | no data | |
| Senior VP & Chief Development Officer | 4.3yrs | no data | 0.040% $ 876.3k | |
| Senior VP & Head of International | 3.3yrs | no data | no data | |
| Senior Vice President of Clinical Development | 3.4yrs | no data | no data |
4.3yrs
Average Tenure
53yo
Average Age
Experienced Management: DCPH's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.1yrs | US$6.01m | 0.084% $ 1.9m | |
| Independent Director | 9.3yrs | US$388.59k | 0% $ 0 | |
| Independent Director | 7.7yrs | US$396.09k | 0% $ 0 | |
| Independent Director | 7.8yrs | US$398.55k | 0% $ 0 | |
| Independent Chairman | 4.5yrs | US$403.30k | 0% $ 0 | |
| Member of Scientific Advisory Board | 9yrs | no data | no data | |
| Independent Director | 16.8yrs | US$414.77k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 9yrs | no data | no data | |
| Member of Scientific Advisory Board | 9yrs | no data | no data | |
| Independent Director | 9.3yrs | US$386.05k | 0.013% $ 281.5k | |
| Member of Scientific Advisory Board | no data | no data | no data |
9.0yrs
Average Tenure
62yo
Average Age
Experienced Board: DCPH's board of directors are considered experienced (9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/11 07:22 |
| End of Day Share Price | 2024/06/11 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Deciphera Pharmaceuticals, Inc. is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | B. Riley Securities, Inc. |
| Arlinda Lee | Canaccord Genuity |
| Charles Duncan | Cantor Fitzgerald & Co. |